期刊
ACTA NEUROLOGICA SCANDINAVICA
卷 118, 期 6, 页码 362-366出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1600-0404.2008.01039.x
关键词
erythropoietin; stroke; neuroprotection; carbamylated erythropoietin; asialic erythropoietin
Recombinant human erythropoietin was produced soon after the discovery of the erythropoietin gene in 1985 and since then, it is used in various clinical conditions such as chronic renal failure. Moreover, experimental studies have shown that erythropoietin exerts neuroprotective action as well. Recently, a clinical trial yielded promising results concerning the use of erythropoietin in stroke management. In this review, we summarize the main data which suggest that recombinant human erythropoietin and its analogues may indeed have a role in stroke treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据